Join Our Newsletter - Get important industry news and analysis sent to your inbox – sign up to our e-Newsletter here

Coronavirus company news summary – QIAGEN gets US FDA authorisation for NeuMoDx™ Vantage Assay test – UK BioBank COVID-19 Antibody Study to use AbC-19™ Rapid Test

30 Mar 2021 (Last Updated March 30th, 2021 09:18)

QIAGEN has received US Food and Drug Administration (FDA) authorisation for the NeuMoDx™ Flu A-B/RSV/SARS-CoV-2 Vantage Assay. The test will help to identify suspected individuals for respiratory viral infection consistent with Covid-19. The test is one more addition to the company’s PCR testing solutions portfolio.

The UK Rapid Test Consortium (UK-RTC) is using the AbC-19™ rapid neutralising antibody test for phase two of the UK Biobank Coronavirus self-test antibody study. The finger-prick home-testing kit gives results in 20 minutes and can detect neutralising IgG antibodies to the full trimeric spike protein of the Covid-19 virus.

Escher Biomedical Diagnostics, a joint venture of Biotrack and Echo Testing Group, has developed a test kit to detect Covid-19 virus in saliva samples. The test is called BT-MED® COV19 Test and used in CLIA-high-complexity laboratories. The testing device includes a fluorescent molecular probe, which is used along with automated intelligent digital image processing to evaluate the presence or absence of the virus.

Ryvex, a clinical diagnostics company, and SD Biosensor, a bio-diagnostic company, have donated over 20,000 rapid antigen test kits to the Organization of Eastern Caribbean States (OECS) countries and to Barbados. The donated kits have been approved by the World Health Organization (WHO) and are expected to be delivered this week.